You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,803,352


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,803,352
Title:Method for continuous visualization of a blood clot or plaque in body lumen
Abstract: A method for visualizing a blood clot or plaque disposed within a body lumen comprising: binding a contrasting complex comprising a contrast material and a thrombolytic material or a clot dissolving agent to the blood clot or plaque; and visualizing the blood clot or plaque over a period time by a visualizing system.
Inventor(s): Fisher; John Steele (Belleair, FL)
Assignee:
Application Number:10/982,990
Patent Claims:1. A method for selectively binding a contrasting complex to a blood clot or a thrombus on a plaque disposed within a body lumen comprising: administering an effective amount of a contrasting complex comprising a contrast material and a thrombolytic material, wherein said contrasting complex: (i) binds or adheres to said blood clot or said thrombus disposed within said body lumen via a fibrin portion of said thrombolytic material for a period of time sufficient to perform an invasive image-guided procedure, wherein said body lumen is selected from the group consisting of: the cardio-vascular system, the pulmonary system, the digestive system, the central nervous system, the reproductive system, and the excretory system; (ii) provides real-time visualization of said blood clot or said thrombus by a visualizing system during said invasive image-guided procedure, wherein said visualizing system is selected from the group consisting of: radiography systems, nuclear medicine systems, ultrasound systems, magnetic resonance systems and any combinations thereof; and (iii) exits said body without causing either kidney toxicity or stimulation of atherogenesis; and visualizing said blood clot or said thrombus by said visualizing system, wherein said contrast material renders radio-opaque said blood clot or said thrombus under x-ray imaging, and wherein said thrombolytic material is selected from the group consisting of: tissue plasminogen activator (tPA) tenecteplase form of TPAse, streptokinase, urokinase, retavase, and any mixtures thereof.

2. The method of claim 1, wherein said image-guided invasive procedure is selected from the group of: manipulation of wires, manipulation of balloons, manipulation of catheters, and manipulation of stents.

3. The method of claim 1, wherein said contrast material is selected from the group consisting of: an ionic material, non-ionic material and mixtures thereof.

4. The method of claim 1, wherein said contrast material comprises at least one heavy atom having an atomic weight of 30 or greater.

5. The method of claim 1, wherein said contrast material comprises at least one metal.

6. The method of claim 1, wherein said contrast material is selected from the group consisting of: iodine, gadolinium, ultrasound contrast materials, and mixtures thereof.

7. The method of claim 1, wherein said contrast material is selected from the group consisting of: metals, paramagnetic materials, high atomic number non-metal materials, radioisotopes, gases or gas precursors, chromatophores, fluorophores, electrical impedance materials, and any combinations thereof.

8. The method according to claim 1, wherein said contrast material binds to said thrombolytic material.

9. The method according to claim 8, wherein the bond between said contrast material and said thrombolytic material is selected from the group consisting of: a molecular bond, an ionic bond, covalent bond, metallic bond, mixed bonds, polar and nonpolar covalent bonds, and multiple bonds.

Details for Patent 7,803,352

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 01/16/1978 ⤷  Try a Trial 2023-03-07
Chiesi Usa, Inc. RETAVASE reteplase For Injection 103786 10/30/1996 ⤷  Try a Trial 2023-03-07
Genentech, Inc. TNKASE tenecteplase For Injection 103909 06/02/2000 ⤷  Try a Trial 2023-03-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.